Reading the Water: Navigating What Matters in Regulatory and Quality

A lot of teams think about regulatory as a gate they need to get through. Pick the path. Build the package. Get the answer. Then move on.

That mindset leaves a lot on the table.

The better way to think about regulatory is as a way to create options. Good strategy is not just about getting to one answer. It is about reducing risk, preserving flexibility, and helping the company move forward without wasting time.

I saw this with a company that had a real opportunity to ask FDA a bigger question tied to a broader future indication. The path would have been harder. Nobody knew for sure how FDA would react. The company had already paid for the work, and we had already written the Breakthrough submission, but they hesitated because they were not sure the data was perfect.

So they waited.

By the time they came back around, the market had moved. About eight months later, a competitor received clearance, which effectively removed their ability to now qualify for Breakthrough. The company then shifted toward a narrower, more conventional strategy. That narrower path may still have made sense in the end. That was never the problem.

The problem was that they lost time and closed a door they did not need to close.

They could have asked the harder question earlier. They could have gotten FDA feedback. They could have kept multiple paths alive while continuing to build the business. They could have used that feedback to shape their study strategy, their investor story, and their next decision point.

Instead, they stayed tied up at the dock.

That is what happens when regulatory is treated like a single track instead of a sequence of strategic decisions.

Sometimes a 510(k) is the right move because it gets a product to market faster, creates early revenue, and helps de-risk what comes next. Sometimes a broader future path remains the real value driver. Sometimes a designation or a narrower initial use is worth pursuing simply because it gives the company more room to maneuver later.

The point is not to pick the biggest path or the fastest path just because it sounds better.

The point is to make each step do something useful:

• Reduce uncertainty
• Create leverage
• Keep future options open

You do not catch much fish with bait sitting on the deck. No matter how good it is, you still need lines in the water.

Regulatory strategy should work the same way. Ask the questions that matter. Keep the right options open. Let each step set up the next one.

That is how you build momentum without boxing the company in.

If you'd like to learn more from Sam about regulatory strategies for greater adoption of your novel medical technology, please contact us.

Sam Murray

Head of Regulatory & Quality